Search

Your search keyword '"Griffin, Michael"' showing total 1,021 results
Start Over Author "Griffin, Michael" Search Limiters Academic (Peer-Reviewed) Journals
1,021 results on '"Griffin, Michael"'

9. Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase

Author

Xie, Stanley C., Wang, Yinuo, Morton, Craig J., Metcalfe, Riley D., Dogovski, Con, Pasaje, Charisse Flerida A., Dunn, Elyse, Luth, Madeline R., Kumpornsin, Krittikorn, Istvan, Eva S., Park, Joon Sung, Fairhurst, Kate J., Ketprasit, Nutpakal, Yeo, Tomas, Yildirim, Okan, Bhebhe, Mathamsanqa N., Klug, Dana M., Rutledge, Peter J., Godoy, Luiz C., Dey, Sumanta, De Souza, Mariana Laureano, Siqueira-Neto, Jair L., Du, Yawei, Puhalovich, Tanya, Amini, Mona, Shami, Gerry, Loesbanluechai, Duangkamon, Nie, Shuai, Williamson, Nicholas, Jana, Gouranga P., Maity, Bikash C., Thomson, Patrick, Foley, Thomas, Tan, Derek S., Niles, Jacquin C., Han, Byung Woo, Goldberg, Daniel E., Burrows, Jeremy, Fidock, David A., Lee, Marcus C. S., Winzeler, Elizabeth A., Griffin, Michael D. W., Todd, Matthew H., and Tilley, Leann

Published
2024
Full Text
View/download PDF

22. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome

Author

Xie, Stanley C., Metcalfe, Riley D., Mizutani, Hirotake, Puhalovich, Tanya, Hanssen, Eric, Morton, Craig J., Du, Yawei, Dogovski, Con, Huang, Shih-Chung, Ciavarri, Jeffrey, Hales, Paul, Griffin, Robert J., Cohen, Lawrence H., Chuang, Bei-Ching, Wittlin, Sergio, Deni, Ioanna, Yeo, Tomas, Ward, Kurt E., Barry, Daniel C., Liu, Boyin, Gillett, David L., Crespo-Fernandez, Benigno F., Ottilie, Sabine, Mittal, Nimisha, Churchyard, Alisje, Ferguson, Daniel, Aguiar, Anna Caroline C., Guido, Rafael V. C., Baum, Jake, Hanson, Kirsten K., Winzeler, Elizabeth A., Gamo, Francisco-Javier, Fidock, David A., Baud, Delphine, Parker, Michael W., Brand, Stephen, Dick, Lawrence R., Griffin, Michael D. W., Gould, Alexandra E., and Tilley, Leann

Published
2021

23. Odd, spoof perfect factorizations

Author

Andersen, Nickolas, Durham, Spencer, Griffin, Michael J., Hales, Jonathan, Jenkins, Paul, Keck, Ryan, Ko, Hankun, Molnar, Grant, Moss, Eric, Nielsen, Pace P., Niendorf, Kyle, Tombs, Vandy, Warnick, Merrill, and Wu, Dongsheng

Published
2022
Full Text
View/download PDF

39. Predictors of the need for atrioventricular nodal ablation following redo ablation for atrial fibrillation.

Author

Calvert, Peter, Wern Yew Ding, Griffin, Michael, Bisson, Arnaud, Koniari, Ioanna, Fitzpatrick, Noel, Snowdon, Richard, Modi, Simon, Luther, Vishal, Mahida, Saagar, Waktare, Johan, Borbas, Zoltan, Ashrafi, Reza, Todd, Derick, Rao, Archana, and Gupta, Dhiraj

Subjects
RISK assessment, T-test (Statistics), STATISTICAL significance, SCIENTIFIC observation, FISHER exact test, RETROSPECTIVE studies, DESCRIPTIVE statistics, ARRHYTHMIA, KAPLAN-Meier estimator, ATRIAL fibrillation, REOPERATION, MEDICAL records, ACQUISITION of data, CATHETER ablation, CARDIAC pacemakers, DATA analysis software, CONFIDENCE intervals, ATRIOVENTRICULAR node, PROPORTIONAL hazards models, REGRESSION analysis
Abstract

Background: Patients who have recurrent atrial fibrillation (AF) following redo catheter ablation may eventually be managed with a pace-and-ablate approach, involving pacemaker implant followed by atrioventricular nodal ablation (AVNA). We sought to determine which factors would predict subsequent AVNA in patients undergoing redo AF ablation. Methods: We analyzed patients undergoing redo AF ablations between 2013 and 2019 at our institution. Follow-up was censored on December 31, 2021. Patients with no available follow- up data were excluded. Time-to-event analysis with Cox proportional hazard regression was used to compare those who underwent AVNA to those who did not. Results: A total of 467 patients were included, of whom 39 (8.4%) underwent AVNA. After multivariable adjustment, female sex (aHR 4.68 [95% CI 2.30-9.50]; p < 0.001), ischemic heart disease (aHR 2.99 [95% CI 1.25-7.16]; p = 0.014), presence of a preexisting pacemaker (aHR 3.25 [95% CI 1.10-9.60]; p = 0.033), and persistent AF (aHR 2.22 [95% CI 1.07-4.59]; p = 0.032) were associated with increased risk of subsequent AVNA requirement. Conclusion: Female sex, ischemic heart disease, and persistent AF may be useful clinical predictors of the requirement for subsequent AVNA and may be considered as part of shared clinical decision making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Craniosynostosis‐associated variants in the IL‐11R complex: new insights and questions.

Author

Sims, Natalie A. and Griffin, Michael D. W.

Subjects
*BRACHYCEPHALY, *INTERLEUKIN receptors, *PROGENITOR cells, *GENETIC variation, *SUTURES, *BONE growth
Abstract

Skull growth involves the expansion of both the flat calvarial bones of the skull and the fibrous marginal zones, termed sutures, between them. This process depends on co‐ordinated proliferation of mesenchymal‐derived progenitor cells within the sutures, and their differentiation to osteoblasts which produce the bone matrix required to expand the size of the bony plates. Defects lead to premature closure of these sutures, termed craniosynostosis, resulting in heterogeneous head shape differences due to restricted growth of one or more sutures. The impact on the individual depends on how many and which sutures are affected and the severity of the effect. Several genetic loci are responsible, including a wide range of variants in the gene for the interleukin 11 receptor (IL11RA, OMIM#600939). Recent work from Kespohl and colleagues provides new insights into how some of these variants influence IL‐11R function; we discuss their influences on IL‐11R structure and IL‐11 function as a stimulus of osteoblast differentiation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Clinical trial evaluation: the EDOSURE clinical trial program.

Author

Griffin, Michael and Lip, Gregory YH

Abstract

EDOSURE is a trial program of the direct oral anticoagulant drug edoxaban, comprising ten randomized clinical trials of which eight are currently published. They evaluate the use of edoxaban in the treatment of nonvalvular atrial fibrillation and acute venous thromboembolism, including in special circumstances such as patients undergoing cardiac procedures, cancer-associated venous thromboembolism, and elderly patients whose bleeding risk precludes conventional anticoagulation strategies. As a result of the collective evidence generated by EDOSURE, edoxaban is now recommended as a treatment option by numerous international guidelines. This review summarizes the context, rationale, and key findings of the studies. EDOSURE is a collection of clinical trials of the medication edoxaban – a blood thinner used to treat or prevent clotting. It encompasses ten trials, eight of which are complete and two are ongoing. Edoxaban's main uses are in patients with atrial fibrillation, or venous clots (e.g., deep vein thrombosis). Trials of blood thinners need to assess the balance of effectiveness (how well the drug treats or prevents clotting) against risk (causing bleeding). These trials collectively demonstrate first that edoxaban is an effective treatment in these conditions and is at least as safe as traditional options like warfarin. Second, in patients with atrial fibrillation who are undergoing procedures like cardiac stenting or ablations, edoxaban is as effective as the previous standard treatments. Finally, in higher-risk populations, such as frail and/or elderly patients, edoxaban can represent a relatively safe option at lower doses. This article is a review of the individual trials, their important findings, and potential limiting factors. Article highlights EDOSURE is an ongoing clinical trial program of edoxaban – a direct oral anticoagulant. In its entirety, it provides an evidence base for edoxaban use in a variety of clinical scenarios, both for nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). Engage-TIMI-48 (2013) found edoxaban (at two different doses – 30 and 60 mg OD) noninferior to warfarin for the prevention of stroke in patients with NVAF. Edoxaban was safer with regard to bleeding events. Hokusai-VTE (2013) assessed edoxaban use in acute VTE. Edoxaban was again noninferior for efficacy (prevention of recurrent VTE), and superior in terms of safety (major or clinically relevant nonmajor bleeding). Ensure AF (2016) found that for NVAF patients undergoing direct current cardioversion, both edoxaban and warfarin represent safe anticoagulant strategies, with very low rates of iatrogenic stroke. However, the study was underpowered for the demonstration of noninferiority. ELIMINATE-AF (2019) assessed NVAF patients undergoing catheter ablation, with the primary efficacy outcome Similarly to Ensure-AF, rates of stroke and bleeding were very low in both warfarin and vitamin K antagonist arms, precluding noninferiority calculations. The authors concluded, however, both are viable options in this patient group. ENTRUST-AF-PCI (2019) examined NVAF patients undergoing percutaneous coronary intervention (PCI), comparing dual therapy with edoxaban + P2Y12 inhibitor, versus triple therapy with warfarin + P2Y12 inhibitor + aspirin. The edoxaban regime was noninferior for efficacy (a composite outcome including stent thrombosis alongside major adverse cardiovascular events), and trended toward superiority for safety (major bleeding). ENVISAGE-TAVI AF (2021) investigated edoxaban use after successful transcatheter aortic valve implantation (TAVI) in patients with concomitant AF. The comparator was a vitamin K antagonist (predominantly warfarin). While noninferiority was reached for efficacy, the main finding from this study was a 40% higher risk of bleeding in the edoxaban arm, a potentially surprising contrast to the other trials discussed in this review. One possible explanation for this difference is the older, frailer population undergoing TAVI compared with the other study cohorts. Hokusai VTE-Cancer (2017) challenged the idea that heparin-derived anticoagulants were the gold standard in cancer-associated VTE. In this study, edoxaban, met noninferiority thresholds for efficacy and safety compared with dalteparin and trended toward a lower rate of recurrent VTE. There was, however, a signal for increased gastrointestinal bleeding in patients with gastrointestinal malignancies. ELDERCARE-AF (2020) was an innovative trial of low-dose edoxaban (15 mg OD) in frail elderly patients who were considered too high risk for traditional anticoagulant medications. Compared with placebo, edoxaban was associated with a 66% reduction in stroke or systemic embolism, at the cost of an increased rate of bleeding, though the latter did not reach statistical significance. STABLED and ENRICH-AF are ongoing trials. STABLED is assessing the effect of catheter ablation on stroke risk, in AF patients who are taking edoxaban. ENRICH-AF is investigating edoxaban versus aspirin use in AF patients with recent intracranial hemorrhage and high predicted stroke risk. Together – these trials support the use of edoxaban for NVAF and VTE across a broad range of specific clinical scenarios. Its bleeding risk profile is generally favorable compared with warfarin, except possibly in older frailer patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Enhanced Catalyst Durability for Bio-Based Adipic Acid Production by Atomic Layer Deposition

Author

Settle, Amy E., Cleveland, Nicholas S., Farberow, Carrie A., Conklin, Davis R., Huo, Xiangchen, Dameron, Arrelaine A., Tracy, Ryon W., Sarkar, Reuben, Kautz, Elizabeth J., Devaraj, Arun, Ramasamy, Karthikeyan K., Watson, Mike J., York, Allyson M., Richards, Ryan M., Unocic, Kinga A., Beckham, Gregg T., Griffin, Michael B., Hurst, Katherine E., Tan, Eric C.D., Christensen, Steven T., and Vardon, Derek R.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results